haloperidol has been researched along with Lipidoses in 3 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Lipidoses: Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids." | 1.38 | In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. ( Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T, 2012) |
| "Phospholipidosis is an adverse effect caused by numerous cationic amphiphilic drugs and can affect many cell types." | 1.36 | Predicting phospholipidosis using machine learning. ( Glen, RC; Lowe, R; Mitchell, JB, 2010) |
| "Cerebrotendinous xanthomatosis is a genetically transmitted disease that is associated with deposition of cholestanol in the central nervous system and Achilles tendons." | 1.27 | Depression in a patient with dementia secondary to cerebrotendinous xanthomatosis. ( Shapiro, S, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lowe, R | 1 |
| Glen, RC | 1 |
| Mitchell, JB | 1 |
| Fischer, H | 1 |
| Atzpodien, EA | 1 |
| Csato, M | 1 |
| Doessegger, L | 1 |
| Lenz, B | 1 |
| Schmitt, G | 1 |
| Singer, T | 1 |
| Shapiro, S | 1 |
3 other studies available for haloperidol and Lipidoses
| Article | Year |
|---|---|
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Bio | 2010 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse | 2012 |
Depression in a patient with dementia secondary to cerebrotendinous xanthomatosis.
Topics: Depressive Disorder; Doxepin; Haloperidol; Humans; Lipidoses; Male; Middle Aged; Neurocognitive Diso | 1983 |